title: TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.
abstract: Early and sustained flow of grade 3 according to Thrombolysis in Myocardial infarction (TIMI) criteria and reocclusion rates are the key measures that define the physiologic efficacy of thrombolytic agents in the treatment of acute myocardial infarction. We performed a systematic overview of angiographic studies after intravenous thrombolysis with accelerated and standard-dose tissue-plasminogen activator (TPA), anisoylated plasminogen streptokinase activator complex (APSAC), and streptokinase. There were 5475 angiographic observations from 15 studies for TIMI flow analysis and 3147 angiographic observations from 27 studies for reocclusion. At 60 and 90 minutes, the rates of TIMI grade 3 flow were 57.1% and 63.2%, respectively, with accelerated TPA, 39.5% and 50.2% with standard-dose TPA, 40.2% and 50.1% with APSAC, and 31.5% at 90 minutes with streptokinase. Overall reocclusion with standard-dose TPA was 11.8% versus 6.0% for accelerated TPA, 4.2% for streptokinase, and 3.0% for APSAC. Although the incidence of TIMI grade 3 flow increased over time with all thrombolytic regimens, decreased patency was observed at 180 minutes with accelerated TPA. Still, accelerated TPA is the most effective agent to establish early (90-minute) TIMI grade 3 flow.
authors.affiliation: Fundación Favaloro, Buenos Aires, Argentina.
authors.forename: N A
authors.initials: NA
authors.lastname: Barbagelata
authors.forename: C B
authors.initials: CB
authors.lastname: Granger
authors.forename: E
authors.initials: E
authors.lastname: Oqueli
authors.forename: L D
authors.initials: LD
authors.lastname: Suárez
authors.forename: M
authors.initials: M
authors.lastname: Borruel
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
mesh_terms: D016255:Anistreplase / Q000627:therapeutic use*; D017023:Coronary Angiography; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D010960:Plasminogen Activators / Q000008:administration & dosage*; D012008:Recurrence; D012039:Regional Blood Flow; D013300:Streptokinase / Q000008:administration & dosage*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D016255:Anistreplase; D013300:Streptokinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator